Hansa Biopharma: Continuing progress with gene therapy partners - Redeye

Hansa’s partner Genethon initiates a phase 2 study based on Imlifidase as a pre-treatment ahead of GNT-0003 in the ultra-rare indication of Crigler-Najjar syndrome.

Länk till analysen i sin helhet: https://www.redeye.se/research/1062878/hansa-biopharma-continuing-progress-with-gene-therapy-partners?utm_source=finwire&utm_medium=RSS